



NDA 21-107/S-008

GlaxoSmithKline
Attention: Olivia Pinkett, Ph.D., M.B.A.
Senior Director, GI/Inflammation
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398

Dear Dr. Pinkett:

Please refer to your supplemental new drug application dated June 25, 2003 (received June 26, 2003), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Lotronex[®] (alosetron hydrochloride) Tablets.

This supplemental new drug application proposes the qualification of a 0.5 mg strength tablet of Lotronex[®] (alosetron hydrochloride) Tablets. In addition, the supplement contains a request for a waiver of the requirement to conduct an *in vivo* bioequivalence study to compare the 0.5 mg tablet to the approved 1 mg tablet of alosetron hydrochloride formulation based on BCS I classification.

We have completed the review of this supplemental application, and it is approved.

In addition, your request for a biowaiver for the 0.5 mg strength tablet is granted based on the demonstration of compositional proportionality to an approved dose strength of the same drug product. Your request for a biowaiver for the 0.5 mg strength based on BCS Class I designation may not be acceptable because alosetron hydrochloride is considered a narrow therapeutic range drug.

The final printed labeling (FPL) must be identical to the attached draft labeling, submitted June 25, 2003.

Please submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. Alternatively, you may submit the FPL electronically according to the guidance for industry titled *Providing Regulatory Submissions in Electronic Format - NDAs* (January 1999). For administrative purposes, this submission should be designated "FPL for approved supplement NDA 21-107/S-008." Approval of this submission by FDA is not required before the labeling is used.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Paul E. Levine, Jr., R.Ph., J.D., Regulatory Health Project Manager, at (301) 443-8347.

Sincerely,

{See appended electronic signature page}

Robert L. Justice, M.D., M.S.

Director

Division of Gastrointestinal
and Coagulation Drug Products

Office of Drug Evaluation III

Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Robert Justice
12/23/03 10:29:33 AM